Literature DB >> 11718941

Approaches for generating recombinant adenovirus vectors.

H Mizuguchi1, M A Kay, T Hayakawa.   

Abstract

Various methods have been developed to facilitate the generation of recombinant adenovirus vectors, and three commercially available methods have been most widely used: the homologous recombination method in E1-complement cell lines, the homologous recombination method in bacteria, and an in vitro ligation method based on simple routine plasmid construction. These methods can insert foreign genes not only into the E1 deletion region, but also into the E3 deletion region, thereby permitting the construction of a binary transgene expression system in which heterologous genes can be inserted into both the E1 and E3 regions. By modifying the latter two methods, fiber-mutant adenovirus vectors can be also constructed in order to modify vector tropism. In this paper, we review recent advances in the construction of first generation adenovirus vectors and fiber-modified adenovirus vectors.

Mesh:

Substances:

Year:  2001        PMID: 11718941     DOI: 10.1016/s0169-409x(01)00215-0

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  8 in total

1.  Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D.

Authors:  Zsolt Ruzsics; Markus Wagner; Andrea Osterlehner; Jonathan Cook; Ulrich Koszinowski; Hans-Gerhard Burgert
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 2.  Delivering the goods: viral and non-viral gene therapy systems and the inherent limits on cargo DNA and internal sequences.

Authors:  Helen Atkinson; Ronald Chalmers
Journal:  Genetica       Date:  2010-01-19       Impact factor: 1.633

3.  Adenovirus vector-based incorporation of a photo-cross-linkable amino acid into proteins in human primary cells and cancerous cell lines.

Authors:  Ayami Kita; Nobumasa Hino; Sakiko Higashi; Kohji Hirota; Ryohei Narumi; Jun Adachi; Kazuaki Takafuji; Kenji Ishimoto; Yoshiaki Okada; Kensaku Sakamoto; Takeshi Tomonaga; Seiji Takashima; Hiroyuki Mizuguchi; Takefumi Doi
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

4.  Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.

Authors:  Cody S Lee; Elliot S Bishop; Ruyi Zhang; Xinyi Yu; Evan M Farina; Shujuan Yan; Chen Zhao; Zongyue Zheng; Yi Shu; Xingye Wu; Jiayan Lei; Yasha Li; Wenwen Zhang; Chao Yang; Ke Wu; Ying Wu; Sherwin Ho; Aravind Athiviraham; Michael J Lee; Jennifer Moriatis Wolf; Russell R Reid; Tong-Chuan He
Journal:  Genes Dis       Date:  2017-04-27

5.  User-Friendly Reverse Genetics System for Modification of the Right End of Fowl Adenovirus 4 Genome.

Authors:  Bingyu Yan; Xiaohui Zou; Xinglong Liu; Jiaming Zhao; Wenfeng Zhang; Xiaojuan Guo; Min Wang; Yingtao Lv; Zhuozhuang Lu
Journal:  Viruses       Date:  2020-03-11       Impact factor: 5.048

6.  Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.

Authors:  Xiaojuan Guo; Yao Deng; Hong Chen; Jiaming Lan; Wen Wang; Xiaohui Zou; Tao Hung; Zhuozhuang Lu; Wenjie Tan
Journal:  Immunology       Date:  2015-04-21       Impact factor: 7.397

7.  Preparation of North American type II PRRSV infectious clone expressing green fluorescent protein.

Authors:  Liyue Wang; Kao Zhang; Hongyu Lin; Wenyan Li; Jiexia Wen; Jianlou Zhang; Yonghong Zhang; Xiujin Li; Fei Zhong
Journal:  Biomed Res Int       Date:  2014-05-08       Impact factor: 3.411

8.  Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.

Authors:  Wei-Xiong Yang; Xiao-Hui Zou; Shuang-Ying Jiang; Nan-Nan Lu; Mei Han; Jian-Hai Zhao; Xiao-Juan Guo; Sheng-Cang Zhao; Zhuo-Zhuang Lu
Journal:  Vaccine       Date:  2016-11-04       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.